247 related articles for article (PubMed ID: 18673461)
41. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
Balarini Lima GA; Machado Ede O; Dos Santos Silva CM; Filho PN; Gadelha MR
Pituitary; 2008; 11(3):287-92. PubMed ID: 17570067
[TBL] [Abstract][Full Text] [Related]
42. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
44. Cabergoline treatment of pregnant women with macroprolactinomas.
Laloi-Michelin M; Ciraru-Vigneron N; Meas T
Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
[No Abstract] [Full Text] [Related]
45. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
46. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
[TBL] [Abstract][Full Text] [Related]
47. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
Behan LA; Draman MS; Moran C; King T; Crowley RK; O'Sullivan EP; Smith D; Thompson CJ; Agha A
Pituitary; 2011 Dec; 14(4):362-6. PubMed ID: 19191028
[TBL] [Abstract][Full Text] [Related]
48. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.
Pivonello R; Matrone C; Filippella M; Cavallo LM; Di Somma C; Cappabianca P; Colao A; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1674-83. PubMed ID: 15070930
[TBL] [Abstract][Full Text] [Related]
49. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Cawood TJ; Bridgman P; Hunter L; Cole D
Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
[No Abstract] [Full Text] [Related]
50. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
51. Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now?
Christoforidis A; Tsakalides C; Anastasiou A; Pavlaki A; Dimitriadou M
Neuro Endocrinol Lett; 2013; 34(4):275-7. PubMed ID: 23803868
[TBL] [Abstract][Full Text] [Related]
52. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy.
Iglesias P; Macho LP; Díez JJ
Age Ageing; 2004 Jul; 33(4):410-2. PubMed ID: 15136289
[TBL] [Abstract][Full Text] [Related]
53. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
54. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
55. Transsphenoidal treatment of secondary empty sella syndrome using low field strength intraoperative MRI: case report.
Kubben PL; Cornips EM; Looij BJ; Beuls EA
Minim Invasive Neurosurg; 2010 Aug; 53(4):198-202. PubMed ID: 21132613
[TBL] [Abstract][Full Text] [Related]
56. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
57. [Treatment of macroprolactinoma with cabergoline during pregnancy].
Forsbach-Sánchez G; Tamez-Pérez HE; Hernández-Herrera R; Bafidis-Lechuga B
Rev Med Inst Mex Seguro Soc; 2009; 47(3):307-10. PubMed ID: 20141661
[TBL] [Abstract][Full Text] [Related]
58. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
Rudman Y; Duskin-Bitan H; Manisterski Y; Pertzov B; Akirov A; Masri-Iraqi H; Shimon I
Clin Endocrinol (Oxf); 2021 Oct; 95(4):606-617. PubMed ID: 34160838
[TBL] [Abstract][Full Text] [Related]
59. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
60. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
